The Relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: A monthly MRI study after triple-dose gadolinium-DTPA

Journal of Neurology

Volumn 251, Issue 4, 2004, Pages 432-439

  Paolillo, Andrea ^a   Piattella, Maria Cristina ^a   Pantano, Patrizia ^a   Di Legge, Silvia ^a   Caramia, Francesca ^a   Russo, Pierluigi ^a,b   Lenzi, Gian Luigi ^a   Pozzilli, Carlo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Brain atrophy; Clinically isolated syndrome; MRI activity; Multiple sclerosis; Triple dose gadolinium DTPA

Indexed keywords

GADOLINIUM PENTETATE;

ADULT; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; MALE; MATHEMATICAL COMPUTING; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; ATROPHY; BRAIN; CONFIDENCE INTERVALS; ECHO-PLANAR IMAGING; FEMALE; FOLLOW-UP STUDIES; GADOLINIUM; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PREDICTIVE VALUE OF TESTS; STATISTICS, NONPARAMETRIC; SYNDROME;

EID: 10944230117     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00415-004-0349-8     Document Type: Article

References (52)

1. Altman DG, Machin D, Bryant TN, Gardner MJ (2000) Statistics with confidence. BMJ Books, Bristol England
2. Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman CH, Comi G, Ader HJ, Losseff N, Valk J (1997) Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120:2059-2069
3. Brex PA, O'Riordan JI, Miskiel KA, Moseley IF, Thompson AJ, Plant GT, Miller DH (1999) Multisequence MRI in clinically isolated syndromes and the early development of MS. Neurology 53:1184-1190
4. Brex PA, Jenkins R, Fox NC, Crum WR, O'Riordan JI, Plant GT, Miller DH (2000) Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology 541:689-691
5. Brex PA, Leary SM, O'Riordan JI, Miszkiel KA, Plant GT, Thompson AJ, Miller DH (2001) Measurement of spinal cord area in clinically isolated syndrome suggestive of MS. J Neurol Neurosurg Psychiatry 70:544-547
6. CHAMPS Study Group (2002) MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group. Neurology 59:998-1005
7. Chard DT, Griffin CM, Parker GJ, Kapoor R, Thompson AJ, Miller DH (2002) Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain 125:327-337
8. Courchesne E, Chisum HJ, Townsend J, Cowles A, Covington J, Egaas B, Harwood M, Hinds S, Press GA (2000) Normal brain development and aging: quantitative analysis at in vivo MR imaging in healthy volunteers. Radiology 216:672-682
9. Dalton CM, Brex PA, Jenkins R, Fox NC, Miszkiel KA, Crum WR, O'Riordan JI, Plant GT, Thompson AJ, Miller DH (2002) Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. J Neurol Neurosurg Psychiatry 73:141-147
10. De Stefano N, Narayanan S, Francis GS, Arnaoutelis R, Tartaglia MC, Antel JP, Matthews PM, Arnold DL (2001) Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 58:65-70
11. De Stefano N, Iannucci G, Sormani MP, Guidi L, Bartolozzi ML, Comi G, Federico A, Filippi M (2002) MR correlates of cerebral atrophy in patients with multiple sclerosis. J Neurol 249:1072-1077
12. Fazekas F, Offenbacher H, Fuchs S, Schmidt R, Niederkorn K, Horner S, Lechner H (1988) Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis. Neurology 38:1822-1825
13. Ferguson B, Matyszak MK, Esiri MM, Perry VH (1997) Axonal damage in acute multiple sclerosis lesions. Brain 120:393-399
14. Filippi M, Grossman RI (2002) MRI technique to monitor MS evolution: the present and the future. Neurology 58:1147-1153
15. Filippi M, Yousry T, Campi A, Kandziora C, Colombo B, Voltz R, Martinelli V, Spuler S, Bressi S, Scotti G, Comi G (1996) Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS. Neurology 46:379-384
16. Filippi M, Rovaris M, Capra R, Gasperini C, Yousry TA, Sormani MP, Prandini F, Horsfield MA, Martinelli V, Bastianello S, Kuhne I, Pozzilli C, Comi G (1998) A multicentre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials. Brain 121:2011-2020
17. Filippi M, Rovaris M, Iannucci G, Mennea S, Sormani MP, Comi G (2000) Whole brain volume changes in progressive MS patients treated with cladribine. Neurology 55:1714-1718
18. Filippi M, Bozzali M, Rovaris M, Gonen O, Kesavadas C, Ghezzi A, Martinelli V, Grossman RI, Scotti G, Comi G, Falini A (2003) Evidence of widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 126:433-437
19. Fisher E, Rudick RA, Simon JH, Cutter G, Baier M, Lee JC, Miller D, Weinstock-Guttman B, Mass MK, Dougherty DS, Simonian NA (2002) Eight-year follow-up study of brain atrophy in patients with MS. Neurology 59:1412-1420
20. Fox NC, Jenkins R, Leary SM, Stevenson VL, Losseff NA, Crum WR, Harvey RJ, Rossor MN, Miller DH, Thompson AJ (2000) Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology 54:807-812
21. Gasperini C, Paolillo A, Giugni E, Galgani S, Bagnato F, Mainero C, Onesti E, Bastianello S, Pozzilli C (2002) MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a. Mult Scler 8:119-123
22. Ge Y, Grossman RI, Udupa JK, Wei L, Mannon LJ, Polansky M, Kolson DL (2000) Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis. Radiology 214:665-670
23. Grimaud J, Lai M, Thorpe J, Wang L, Barker GJ, Plummer DL, Tofts PS, McDonald WI, Miller DH (1996) Quantification of MRI lesion load in multiple sclerosis: a comparison of three computer-assisted techniques. Magn Reson Imaging 14:495-505
24. Kalkers NF, Ameziane N, Bot JC, Minneboo A, Polman CH, Barkhof F (2002) Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. Arch Neurol 59:1572-1576
25. Kalkers NF, Vrenken H, Uitdehaag BMJ, Polman CH, Barkhof F (2002) Brain atrophy in multiple sclerosis: impact of lesions and of damage of whole brain tissue. Mult Scler 8:410-414
26. Kuhlmann T, Lingfeld G, Bitsh A, Schuchardt J, Bruck W (2002) Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 125:2202-2212
27. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444-1452
28. Lee MA, Smith S, Palace J, Matthews PM (1998) Defining multiple sclerosis disease activity using MRI T2-weighted difference imaging. Brain 121:2095-2102
29. Leist TP, Gobbini MI, Frank JA, McFarland HF (2001) Enhancing magnetic resonance imaging lesions and cerebral atrophy in patients with relapsing multiple sclerosis. Arch Neurol 58:57-60
30. Lin X, Blumhardt LD (2001) Inflammation and atrophy in multiple sclerosis: MRI associations with disease course. J Neurol Sci 189:99-104
31. Losseff NA, Wang L, Lai HM, Yoo DS, Gawne-Cain ML, McDonald WI, Miller DH, Thompson AJ (1996) Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 19:2009-2019
32. Luks TL, Goodkin DE, Nelson SJ, Majumdar S, Bacchetti P, Portnoy D, Sloan R (2000) A longitudinal study of ventricular volume in early relapsing-remitting multiple sclerosis. Mult Scler 6:332-337
33. Miller DH, Grossman RI, Reingold SC, McFarland HF (1998) The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 121:3-24
34. Miller DH, Barkhof F, Frank JA, Parker GJ, Thompson AJ (2002) Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 125:1676-1695
35. Molyneux PD, Kappos L, Polman C, Pozzilli C, Barkhof F, Filippi M, Yousry T, Hahn D, Wagner K, Ghazi M, Beckmann K, Dahlke F, Losseff N, Barker GJ, Thompson AJ, Miller DH (2000) The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. Brain 123:2256-2263
36. Paolillo A, Coles AJ, Molyneux PD, Gawne-Cain M, MacManus D, Barker GJ, Compston DA, Miller DH (1999) Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 53:751-757
37. Paolillo A, Pozzilli C, Gasperini C, Giugni E, Mainero C, Giuliani S, Tomassini V, Millefiorini E, Bastianello S (2000) Brain atrophy in relapsing-remitting multiple sclerosis: relationship with 'black holes', disease duration and clinical disability. J Neurol Sci 174:85-91
38. Pfefferbaum A, Mathalon DH, Sullivan EV, Rawles JM, Zipursky RB, Lim KO (1994) A quantitative magnetic resonance imaging study of changes in brain morphology from infancy to late adulthood. Arch Neurol 51:874-887
39. Poser CM, Paty DW, Scheimberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227-231
40. Redmond IT, Barbosa S, Blumhardt LD, Roberts N (2000) Short-term ventricular volume changes on serial MRI in multiple sclerosis. Acta Neurol Scand 102:99-105
41. Rovaris M, Comi G, Rocca MA, Wolinsky JS, Filippi M (2001) European/Canadian Glatiramer Acetate Study Group. Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain 124: 1803-1812
42. Rudick RA, Fisher E, Lee J-C, Simon J, Jacobs L (1999) Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology 53:1698-1704
43. Saindane AM, Ge Y, Udupa JK, Babb JS, Mannon LJ, Grossman RI (2000) The effect of gadolinium-enhancing lesions on whole brain atrophy in relapsing-remitting MS. Neurology 55:61-65
44. Silver NC, Good CD, Barker GJ, MacManus DG, Thompson AJ, Moseley IF, McDonald WI, Miller DH (1997) Sensitivity of contrast enhanced MRI in multiple sclerosis: effects of gadolinium dose, magnetization transfer contrast and delayed imaging. Brain 120: 1149-1161
45. Simon JH (1999) From enhancing lesions to brain atrophy in relapsing MS. J Neuroimmunol 98:7-15
46. rd, Brownscheidle CM (1999) A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 53:139-148
47. Smith SM, De Stefano N, Jenkinson M, Matthews PM (2001) Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr 25:466-475
48. Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, Federico A, De Stefano N (2002) Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 17:479-489
49. Stevenson VL, Smith SM, Matthews P, Miller DH, Thompson AJ (2002) Monitoring disease activity and progression in primary progressive multiple sclerosis using MRI: sub voxel registration to identify lesion changes and to detect cerebral atrophy. J Neurol 249:171-177
50. Stone LA, Albert PS, Smith ME, DeCarli C, Armstrong MR, McFarlin DE, Frank JA, McFarland HF (1995) Changes in the amount of diseased white matter over time in patients with relapsing remitting multiple sclerosis. Neurology 45:1808-1814
51. Trapp BD, Peterson J, Ranshoff RM, Rudick R, Mork S, Bo L (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278-285
52. Zivadinov R, Sepcic J, Nasuelli D, De Masi R, Bragadin LM, Tommasi MA, Zambito-Marsala S, Moretti R, Bratina A, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M (2001) A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 70:773-780